潘婷婷, 任益民, 叶延程, 张雁山, 祁英, 马有国, 陈东基, 陈威佐. 碳离子治疗肿瘤的临床进展研究[J]. 中国肿瘤临床, 2023, 50(18): 951-956. DOI: 10.12354/j.issn.1000-8179.2023.20230818
引用本文: 潘婷婷, 任益民, 叶延程, 张雁山, 祁英, 马有国, 陈东基, 陈威佐. 碳离子治疗肿瘤的临床进展研究[J]. 中国肿瘤临床, 2023, 50(18): 951-956. DOI: 10.12354/j.issn.1000-8179.2023.20230818
Tingting Pan, Yimin Ren, Yancheng Ye, Yanshan Zhang, Ying Qi, Youguo Ma, Dongji Chen, Weizuo Chen. Clinical research progress of carbon ion radiotherapy for cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 50(18): 951-956. DOI: 10.12354/j.issn.1000-8179.2023.20230818
Citation: Tingting Pan, Yimin Ren, Yancheng Ye, Yanshan Zhang, Ying Qi, Youguo Ma, Dongji Chen, Weizuo Chen. Clinical research progress of carbon ion radiotherapy for cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 50(18): 951-956. DOI: 10.12354/j.issn.1000-8179.2023.20230818

碳离子治疗肿瘤的临床进展研究

Clinical research progress of carbon ion radiotherapy for cancer

  • 摘要: 碳离子束拥有独特的物理学及生物学优势,在肿瘤治疗过程中具有高效性和低毒性,并且整体治疗周期短,因此被认为是21世纪最理想的肿瘤放射治疗射线。但是碳离子中心建设及设备运营费用昂贵,目前世界范围内,仅有日本、德国、中国、意大利、奥地利等极少数国家将碳离子应用于临床。自1994年以来,日本一直应用碳离子束治疗恶性肿瘤,治疗效果较好。截至2022年底,全球范围内超过46 800例患者接受了碳离子治疗,其中包括头颈部恶性肿瘤、肺癌、肝癌、胰腺癌等。本文总结近20年来碳离子在临床应用中的经验、治疗效果、最新发展及其作为一种新兴癌症治疗方式的优点,并将碳离子治疗与传统的光子放疗疗效及不良反应进行比较,可以帮助临床进一步了解碳离子治疗的优势及进展,并且指导关于新的碳离子治疗中心的建设,从而更好地服务于肿瘤患者。

     

    Abstract: The use of carbon ion beam therapy for tumor treatment offers unique physical and biological advantages, high efficiency, low toxicity, and a short treatment cycle. Therefore, it is considered to be the most ideal radiation therapy for cancer in the 21st century. However, construction and equipment operation costs for a carbon ion center are prohibitive. Currently, carbon ions are only used for clinical purposes in Japan, Germany, China, Italy, Austria, and a few other countries. In Japan, patients with cancer have been treated with carbon ions since 1994, with strong positive effects. To date, over 46,800 patients worldwide have undergone carbon ion radiotherapy (CIRT) for conditions such as malignant head and neck tumors as well as lung cancer, liver cancer, pancreatic cancer, and other cancer types. We conducted a review encompassing over 20 years of global clinical experience with CIRT to summarize treatment outcomes, recent developments, and the merits of CIRT as an emerging cancer treatment modality. We also compare its efficacy and toxicity with those of photon radiotherapy. These findings can serve as a useful reference in decision making and planning regarding new heavy ion centers to better serve patients with cancer.

     

/

返回文章
返回